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The prevalence of hepatitis B virus (HBV) and hepatitis C virus
(HCV) infection in patients with haematological and solid malig-
nancies is increased compared with the general population
worldwide. There is currently a consensus that immune suppres-
sive and/or anti-neoplastic therapy in patients with overt or
occult HBV pose a serious, but usually preventable threat of liver
injury and failure in such patients [1]. HBV reactivation has been
reported in 14–70% of patients undergoing chemotherapy and
especially in those treated with corticosteroids and rituximab.
Consequently, the AASLD and EASL recommend pre-treatment
screening and pre-emptive protection with an anti-viral agent
for HBV patients at risk [2,3]. In contrast, the deﬁnition, the risk,
and consequences of HCV reactivation in such patient popula-
tions undergoing immunosuppressive and chemotherapy are less
clear as reﬂected in a number of recent reports [4–10]. In this
context, and regardless of whether the patient has HBV or HCV,
one has to distinguish between acute exacerbation of an underly-
ing liver disease in immune suppressed patients, which is not
necessarily caused by viral reactivation (i.e., infection or drug
induced liver injury), and the direct or indirect effects of viral
reactivation per se. Except for some anecdotal case reports with
a fatal outcome, a literature search between 1996 and 2012 failed
to identify large scale studies reporting severe hepatic dysfunc-
tion in HCV patients undergoing immuno or chemotherapy
[10]. Already in 1998, Zuckerman and co-workers retrospectively
evaluated 27 viremic HCV patients undergoing chemotherapy for
hematologic malignancies of whom 55% developed a mild to
moderate ALT ﬂare (range 59–491 U/L) which appeared within
2–3 weeks following cessation of chemotherapy (protocols did
not include anti CD20 – rituximab) while none developed liver
failure [4]. The conclusion of the authors that signiﬁcant hepatic
dysfunction is uncommon among HCV infected patients treated
with chemotherapy for hematologic malignancies seems still
valid 14 years later, even after widespread incorporation of ritux-
imab into the treatment protocols.Journal of Hepatology 20
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E-mail address: shouval@hadassah.org.ilA recent survey in Italy has followed 207 consecutive non-
Hodgkin lymphoma (NHL) patients of whom 9.2% were infected
with HCV and treated with CHOP with or without rituximab.
The incidence of hepatitis ﬂares, although again relatively mild,
was 26.3% vs. 2.1% among HCV+ patients as compared to
non-infected controls. Further case reports have been published
which link the relatively mild ﬂares observed in such HCV
patients to treatment, mainly with rituximab and possibly with
some other chemotherapeutic agents. Yet, in most of these cases,
it is difﬁcult if not impossible, to distinguish between acute exac-
erbation of liver disease (potentially due to non-viral causes) and
HCV re-activation. One reason for this difﬁculty is the lack of pro-
spective follow-up of the HCV viral load at ﬁxed intervals in rela-
tion to ALT ﬂuctuations and chemotherapeutic regimen. In
reactivating HBV patients undergoing chemotherapy, enhanced
viral replication usually precedes hepatocellular injury which fre-
quently appears following withdrawal of anti-neoplastic therapy
and recovery of the immune system. In contrast, conﬂicting data
have been reported in HCV patients receiving similar chemother-
apy where enhanced viral replication was documented before,
during or after an ALT ﬂare [5–10]. The similarities and differ-
ences in the risk factors, the patho-physiologic mechanisms lead-
ing to liver injury and the prognosis in HBV and HCV patients
undergoing chemotherapy have captured the attention of a num-
ber of investigators in the past two years [6–10].
In the present issue of the Journal, Mahale and co-workers
from the MD Anderson Institute in the US, retrospectively identi-
ﬁed 33/308 cancer patients with acute exacerbation of liver dys-
function, most of them with hematologic malignancies and nine
with solid tumors, infected with HCV (42% genotype 1). Diagnosis
was established via detection of anti-HCV antibodies and con-
ﬁrmed through detection of circulating HCV-RNA by PCR [11]. A
control group consisted of 32 anti-HCV+ patients, negative for
HCV-RNA. The investigators deﬁned an acute exacerbation of
liver disease by at least a threefold rise in ALT while HCV reacti-
vation was deﬁned arbitrarily through a 1log10 rise in HCV-RNA.
The main ﬁndings of this survey suggest that about 11% of
patients with persistent HCV infection developed an acute exac-
erbation of their liver disease in association with immuno/che-
motherapy and particularly with administration of rituximab.
The study population consisted mainly of males at a median
age of 55 years. Multivariate analysis suggests that the risk for
exacerbation of liver disease was proportional to an increased12 vol. 57 j 1161–1162
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dosing of rituximab, but was not affected by administration of
corticosteroids. Chemotherapy had to be discontinued, at least
temporarily, in 45% of patients with acute exacerbation of liver
dysfunction as compared to 11% in patients with preserved hepa-
tic functions. Information on HCV viral load was only available for
22/33 patients with acute exacerbation, of whom 8 patients (36%)
developed a median rise in viral load above baseline of
1.45 log10 IU/ml, which was interpreted as evidence for viral re-
activation in the absence of other causes of liver dysfunction.
The rates of cirrhosis (diagnosed mainly radiologically, and histo-
logically in a minority of patients), were similar, ranging between
23% and 25% in patients with or without exacerbation, respec-
tively. Surprisingly, in patients who discontinued chemotherapy
due to acute exacerbation, cirrhosis was less frequent at baseline
as compared to patients without exacerbation. A 10-fold rise in
ALT levels was present in 14/33 HCV patients, of whom 10
patients were treated with protocols containing rituximab. Yet,
none developed fulminant liver failure and the median peak of
ALT levels was similar in both study groups. The one-year out-
come as well as the median survival was similar in both groups
as well (data not shown). Finally, none of the 32 anti-HCV+/
HCV-RNA- patients receiving chemo or immunosuppressive
treatment developed an acute exacerbation of liver disease.
The results of this important study strengthen and conﬁrm a
number of sporadic observations that chemo and especially
immunetherapy with rituximab and possibly with several other
antineoplastic agents can indeed trigger HCV reactivation and
lead to exacerbation of previously silent liver disease. At ﬁrst
look, this phenomenon reminds us of the by now well character-
ized risk of HBV reactivation in patients with persistent HBV
infection treated by immuno and chemotherapy. Indeed, there
are quite a number of similarities between both groups of
patients at risk. These include, among others, the presence of per-
sistent viral infection, the perceived relationship between treat-
ment-induced impaired immunity and emerging hepatocellular
injury, the overwhelming impact of rituximab treatment on B cell
functions, and the disruption in treatment of the underlying
tumors as a result of liver dysfunction. There are, however, a
number of dissimilarities between these DNA and RNA virus
infected patients. In the present study and in contrast to the sit-
uation in HBV, administration of corticosteroids was not associ-
ated with an increased risk for acute exacerbation and viral
reactivation. The rates and severity of HCV reactivation seem to
be much lower in patients with HCV infection as compared to
HBV reactivation, which has repeatedly been linked to develop-
ment of fulminant hepatitis and death. HBV reactivation can be
prevented through vaccination or pre-emptive treatment with
an anti-viral agent in patients at risk. In contrast, at present,
HCV cannot be prevented by vaccination, and effective anti-viral
treatment in heavily immune suppressed hemato-oncologic
patients with reactivating HCV is not a viable option.
In contrast to HBV, little is known about the pathogenesis of
HCV infection in immune-suppressed patients. It has already
been repeatedly hypothesized that immune suppression in HBV
as well as in HCV infection may lead to enhanced viral replica-
tion, which serves as trigger for liver injury after recovery of
the immune system, within weeks to months following cessation
of anti-neoplastic treatment [10]. Yet, proof for this hypothesis is
still lacking, particularly in the case of HCV infection. Regretfully,
only 22 of the HCV patients, which represent 7% of the entire
study cohort, were tested for HCV-RNA before and after treat-1162 Journal of Hepatology 2012ment. The correlation between ALT levels and ﬂuctuations in viral
load presented for nine patients in Fig. 4, does not enable a clear
conclusion whether enhanced viral replication precedes hepato-
cellular injury, as described for most HBV patients under similar
circumstances.
The study has a number of limitations as also acknowledged
by the authors. The retrospective design as well as the exclusion
of 261 anti-HCV+ patients from analysis may have led to a bias in
assessment of HCV reactivation rates. Furthermore, asymptom-
atic exacerbations could have been missed. Longer follow-up is
warranted in patients with reactivated HCV infection.
Regardless of these limitations, the study results are a timely
contribution to an increased awareness by hemato-oncologists
and hepatologists alike regarding the risk of HCV reactivation
among their patients. Although less frequent and less severe as
compared to HBV infection, HCV reactivation can lead to serious
disruption of treatment in such patients and pre-treatment
screening through anti-HCV testing is a simple and low cost pro-
cedure. The results of this report justify the design of a prospec-
tive study with predeﬁned periodic measurements of HCV-RNA
and ALT in HCV patients treated with immune suppressive and
cytotoxic agents.Conﬂict of interest
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